Iridium

Dosage for Iridium must be highly individualized, based on the patient's sensitivity level and the specific clinical indication. There is no 'one-size-fits-all' dose.

• Maintenance Immunotherapy: For most adults, the target maintenance dose ranges from 0.5 mL to 1.0 mL of the highest concentration (e.g., 10,000 BAU/mL or 1:100 w/v) administered every 4 to 8 weeks.
• Build-up Phase: The initial dose typically starts extremely low, often at 0.05 mL of a 1:100,000 dilution. Doses are increased weekly or bi-weekly by 50% to 100% until the maintenance dose is reached, provided the patient tolerates the injections without significant local or systemic reactions.
• Diagnostic Testing: For skin prick testing, a single drop of the concentrated extract is used. For intradermal testing, 0.02 mL to 0.05 mL of a 1:1,000 or 1:100 dilution is injected into the superficial dermis.

Iridium is approved for use in children, typically those aged 5 years and older. The dosing principles for pediatric patients are similar to those for adults, focusing on the patient's immunological response rather than body weight.

• Pediatric Build-up: Pediatric patients may require a more conservative build-up schedule to monitor for adverse reactions. The starting dose is usually the same as adults (low dilution), with adjustments made based on the size of the local reaction at the injection site.
• Safety Note: Use in children under 5 years of age is generally reserved for severe cases where the risk of future anaphylaxis outweighs the risks of immunotherapy, as young children may have difficulty communicating early symptoms of a systemic reaction.

Renal Impairment

No specific dose adjustments are typically required for patients with renal impairment, as the protein components are metabolized by proteases. However, patients with severe renal disease should be monitored closely for systemic fluid balance if receiving large volumes of diluent.

Hepatic Impairment

No dosage adjustments are necessary for hepatic (liver) impairment. The clearance of Iridium is not dependent on hepatic CYP450 metabolism.

Elderly Patients

Elderly patients (65 years and older) should be evaluated for cardiovascular stability before starting Iridium. If the patient is taking beta-blockers for hypertension or heart disease, the dose may need to be adjusted or the medication changed, as beta-blockers can interfere with the effectiveness of epinephrine if an emergency occurs.

Iridium must be administered under the direct supervision of a healthcare professional prepared to treat anaphylaxis.

• Administration: For SCIT, the injection is given subcutaneously in the posterior aspect of the upper arm. The site should be rotated between the left and right arms with each visit.
• Observation Period: Patients must remain in the medical office for at least 30 minutes after every injection to monitor for signs of a systemic allergic reaction.
• Storage: Iridium extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect from light to prevent degradation of the allergenic proteins.
• Food/Drink: There are no specific food restrictions, but patients should avoid vigorous exercise for 2 hours before and after the injection to prevent rapid absorption of the allergen.

If a dose is missed during the build-up phase, the next dose may need to be reduced to ensure safety.

• 1-2 weeks late: Repeat the last dose.
• 3-4 weeks late: Reduce the dose by one or two steps in the build-up schedule.
• >4 weeks late: Consult your allergist; you may need to restart the build-up from a much lower concentration.

An 'overdose' of Iridium typically manifests as an immediate systemic allergic reaction or anaphylaxis.

• Signs: Hives (urticaria), swelling of the throat (angioedema), wheezing, shortness of breath, rapid heart rate, or a drop in blood pressure (fainting).
• Emergency Measures: Immediate administration of epinephrine (adrenaline) is the first-line treatment. High-flow oxygen, intravenous fluids, and antihistamines may also be required. If an overdose is suspected outside of a clinical setting (e.g., with SLIT), call 911 immediately.

> Important: Follow your healthcare provider's dosing instructions precisely. Do not adjust your dose or skip visits without medical guidance, as this increases the risk of reactions.

The most frequent side effects associated with Iridium involve local reactions at the site of administration. These are generally considered part of the body's natural response to the allergen and do not necessarily indicate a need to stop treatment.

• Injection Site Redness (Erythema): A red patch at the site of the shot, usually appearing within minutes and resolving within 24 hours.
• Local Swelling (Edema): A raised bump or 'wheal' at the injection site. If the swelling is smaller than the size of a half-dollar (approx. 3 cm), it is considered a normal local reaction.
• Itching (Pruritus): Intense itching at the injection site or occasionally in the palms of the hands or soles of the feet.
• Tenderness: Mild pain or aching in the arm where the injection was given, similar to a flu shot.

These reactions are more significant and may require a temporary adjustment of the Iridium dose.

• Large Local Reactions (LLR): Swelling that exceeds 5-10 cm in diameter or involves the entire upper arm. This may peak 6-12 hours after the injection.
• Fatigue: A general feeling of tiredness or 'malaise' following the treatment session.
• Headache: Mild to moderate tension-type headaches.
• Nasal Congestion: Temporary worsening of hay fever symptoms (sneezing, runny nose).

• Generalized Hives: Itchy welts appearing on parts of the body away from the injection site.
• Mild Wheezing: A whistling sound when breathing, indicating slight airway constriction.
• Gastrointestinal Upset: Nausea or mild abdominal cramping shortly after administration.

> Warning: Stop taking Iridium and call your doctor or emergency services immediately if you experience any of these signs of Anaphylaxis:

• Difficulty Breathing: Feeling as though your throat is closing or having severe shortness of breath.
• Swelling of the Tongue or Throat: Visible swelling that interferes with swallowing or speaking.
• Rapid Drop in Blood Pressure: Feeling dizzy, lightheaded, or fainting (syncope).
• Rapid or Weak Pulse: A heart rate that feels fast, fluttering, or difficult to find.
• Cyanosis: A bluish tint to the lips, fingernails, or skin, indicating lack of oxygen.
• Sense of Impending Doom: An intense feeling of anxiety or fear that often precedes a severe systemic reaction.

Iridium is generally well-tolerated over long periods (3-5 years of therapy). However, some patients may develop:

• Persistent Subcutaneous Nodules: Small, hard lumps under the skin at the injection site that may take weeks or months to disappear.
• Immunological Shift: While usually beneficial, some patients may develop new sensitivities to other allergens, though this is rare and often unrelated to the Iridium itself.
• Chronic Fatigue: In very rare cases, patients report ongoing lethargy during the years of maintenance therapy.

WARNING: RISK OF SEVERE ALLERGIC REACTIONS

Iridium, as a Standardized Insect Allergenic Extract, can cause severe, life-threatening systemic allergic reactions, including anaphylaxis.

• Iridium must only be administered in a healthcare setting by personnel trained in the management of anaphylaxis.
• Patients must be observed for at least 30 minutes following administration.
• Iridium may not be suitable for patients with unstable asthma or those taking certain medications like beta-blockers.
• Patients should be prescribed and trained in the use of an epinephrine auto-injector for emergency use.

Report any unusual symptoms to your healthcare provider immediately. Even a 'mild' systemic reaction (like widespread itching) can be a precursor to a more severe reaction in the future.

Iridium is a potent biological agent. Its safety depends heavily on proper administration and patient selection. Patients must be transparent with their allergist about their current health status, especially regarding respiratory and cardiovascular health. Any change in health, such as a new pregnancy or a new heart medication, must be reported before the next dose of Iridium is administered.

No FDA black box warnings for Iridium. Note: While the FDA requires specific 'Boxed Warnings' for many sublingual immunotherapy tablets (SLIT), standardized injectable extracts like Iridium typically carry prominent 'Warnings and Precautions' regarding anaphylaxis rather than a formal Black Box format. However, the risk of anaphylaxis is the primary clinical concern and is treated with the same level of gravity.

• Anaphylaxis Risk: This is the most significant risk. Anaphylaxis can occur even in patients who have previously tolerated Iridium for years. The risk is higher during the build-up phase and in patients with high levels of sensitivity.
• Asthma Stability: Patients with poorly controlled or unstable asthma are at a significantly higher risk for severe respiratory complications during Iridium therapy. If your peak flow meter readings are down or you are using your rescue inhaler more often, notify your doctor before your injection.
• Cardiovascular Disease: Patients with pre-existing heart conditions may be less able to tolerate the physiological stress of a systemic reaction or the effects of epinephrine used to treat such a reaction.
• Beta-Blocker Interaction: These medications (e.g., metoprolol, propranolol) can make an allergic reaction more difficult to treat because they block the effects of epinephrine.

• Pre-Injection Assessment: Before every dose, the clinician will ask about any reactions to the previous dose and your current asthma symptoms.
• 30-Minute Wait: This is a mandatory monitoring period. Most fatal reactions to allergenic extracts occur within 30 minutes of the injection.
• Lung Function: Periodic spirometry or peak flow testing may be required for patients with a history of asthma.
• Skin Site Inspection: The injection site must be checked for large local reactions before the patient leaves the clinic.

Iridium does not typically cause sedation. However, if a patient experiences a systemic reaction or receives epinephrine, they should not drive or operate machinery until they have been cleared by a physician. Some patients feel 'foggy' or tired after an injection and should use caution.

Alcohol should be avoided on the day of an Iridium injection. Alcohol causes vasodilation (widening of blood vessels), which can increase the rate at which the allergen is absorbed into the bloodstream, potentially increasing the risk of a systemic reaction.

Iridium therapy is typically a long-term commitment (3 to 5 years). Stopping therapy early may result in the return of severe allergic sensitivity.

• Tapering: There is no physical 'withdrawal' from Iridium, so tapering is not required for the patient's comfort. However, if therapy is paused for more than a few weeks, a 're-start' protocol with lower doses is necessary to safely resume treatment.

> Important: Discuss all your medical conditions, especially asthma and heart problems, with your healthcare provider before starting Iridium.

• Beta-Adrenergic Blockers (Beta-Blockers): While not an absolute contraindication in all cases, the use of Iridium with beta-blockers (e.g., atenolol, carvedilol) is generally avoided. The clinical consequence is that if the patient has an anaphylactic reaction to Iridium, the beta-blocker will prevent epinephrine from working effectively, potentially leading to a fatal outcome. Management: Switch to an alternative blood pressure medication (like an ACE inhibitor) if possible.

• ACE Inhibitors: Some studies suggest that patients taking ACE inhibitors (e.g., lisinopril, enalapril) may be at an increased risk for more severe systemic reactions during immunotherapy, particularly with insect venoms. Mechanism: ACE inhibitors interfere with the breakdown of bradykinin, a substance involved in allergic inflammation.
• MAO Inhibitors (MAOIs): Medications like phenelzine or selegiline can potentiate the effects of sympathomimetic amines (like epinephrine). If a patient on an MAOI requires epinephrine for an Iridium reaction, they may experience a dangerous spike in blood pressure.
• Tricyclic Antidepressants (TCAs): Similar to MAOIs, TCAs (e.g., amitriptyline) can increase the cardiovascular effects of epinephrine, requiring extreme caution during emergency treatment.

• Antihistamines: While often used to manage local reactions, taking a strong antihistamine (e.g., diphenhydramine) right before an Iridium injection might mask the early 'warning signs' of a systemic reaction, such as mild itching or sneezing. This could delay the recognition of anaphylaxis.
• Systemic Corticosteroids: Long-term use of prednisone may slightly blunt the immune system's response to Iridium, potentially reducing the overall efficacy of the desensitization process.

• High-Fat Meals: There is no direct interaction, but heavy meals immediately before an injection can occasionally cause gastrointestinal discomfort that might be confused with a systemic reaction.
• Alcohol: As noted previously, alcohol increases blood flow and can lead to faster systemic absorption of the Iridium proteins, increasing reaction risk.

• St. John's Wort: May theoretically affect the metabolism of co-administered vitamins (like Vitamin D in some Iridium formulations) through CYP3A4 induction.
• Feverfew/Ginkgo Biloba: These supplements have mild anti-platelet effects. While not a major risk, they could theoretically increase the risk of bruising at the injection site.

• Skin Testing: If a patient is receiving Iridium immunotherapy, their skin reactivity to that specific allergen will decrease over time. This is an expected clinical outcome, not an 'interference.'
• Serum IgE: Total IgE levels may temporarily rise at the start of Iridium therapy before eventually declining. This should be interpreted carefully by an immunologist.

For each major interaction, the primary strategy is prevention and monitoring. If you must remain on a beta-blocker, your doctor will perform a rigorous risk-benefit analysis before proceeding with Iridium therapy.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including over-the-counter allergy meds.

Iridium must NEVER be used in the following circumstances:

1. 1Severe, Unstable Asthma: If a patient's asthma is not well-controlled (e.g., FEV1 consistently below 70% of predicted), the risk of a fatal respiratory reaction to Iridium is unacceptably high. The mechanism is that the allergen can trigger immediate bronchospasm that the patient's compromised lungs cannot handle.
2. 2Recent Myocardial Infarction (Heart Attack): Patients who have had a heart attack within the last 3-6 months should not start Iridium. The physiological stress of a potential allergic reaction or the administration of emergency epinephrine could cause further cardiac damage.
3. 3History of Severe Reaction to the Diluent: Iridium extracts contain inactive ingredients like phenol or glycerin. If a patient is known to be severely allergic to these specific chemicals, the extract cannot be used.

These conditions require a careful risk-benefit analysis by a specialist:

• Autoimmune Disorders: There is a theoretical concern that stimulating the immune system with Iridium could worsen conditions like Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis. However, many patients with these conditions successfully undergo immunotherapy.
• Malignancy (Cancer): Patients with active cancer or those undergoing chemotherapy may have unpredictable immune responses.
• Severe Atopic Dermatitis: While not a contraindication, severe skin disease can make it difficult to interpret skin tests or monitor for hives.
• Beta-Blocker Therapy: As discussed, this is a relative contraindication due to the interference with emergency treatment (epinephrine).

Patients who are sensitive to one member of an insect family (e.g., Yellow Jackets) may show cross-sensitivity to others (e.g., Hornets) when using Iridium extracts. This is because the proteins in these venoms are structurally similar. Your doctor will use this information to create a 'cocktail' of extracts that covers all relevant sensitivities.

> Important: Your healthcare provider will evaluate your complete medical history, including your lung function and heart health, before prescribing Iridium.

FDA Pregnancy Category: C (Standard for most allergenic extracts).

• Risk Summary: There are no adequate and well-controlled studies of Iridium in pregnant women. However, the primary risk during pregnancy is not the Iridium itself, but the potential for maternal anaphylaxis, which can cause fetal hypoxia (lack of oxygen to the baby).
• Clinical Guidance: It is generally recommended not to start Iridium immunotherapy during pregnancy. If a woman is already on a maintenance dose and becomes pregnant, the therapy may be continued at that same dose (without further increases) if the risk of a natural allergic reaction (e.g., from a wild insect sting) is considered greater than the risk of the shots.

It is not known whether Iridium allergenic proteins are excreted in human milk. However, because these are large proteins that are likely digested in the infant's stomach, the risk to a nursing infant is considered very low. Breastfeeding is generally not a reason to discontinue Iridium therapy.

Iridium is widely used in children.

• Approved Age: Usually 5 years and older.
• Considerations: Children often respond more robustly to immunotherapy than adults. The main challenge is the child's ability to report early symptoms of a reaction. Close monitoring and 'distraction techniques' during the 30-minute wait are essential.
• Growth: There is no evidence that Iridium therapy affects growth or development in children.

Patients over age 65 require special consideration:

• Cardiovascular Health: Higher prevalence of heart disease and hypertension.
• Polypharmacy: Increased likelihood of taking interacting medications like beta-blockers or ACE inhibitors.
• Renal Function: While not a primary clearance route, overall frailty may affect the body's ability to recover from a systemic reaction.

No specific dose adjustments are required for patients with kidney disease. However, clinicians should be mindful of the total volume of saline diluent used if the patient is on strict fluid restrictions (e.g., end-stage renal disease).

Liver disease does not alter the processing of Iridium extracts. No adjustments are necessary for patients with any stage of hepatic impairment (Child-Pugh A, B, or C).

> Important: Special populations require individualized medical assessment. Always inform your doctor if you are planning to become pregnant or have new health changes.

Iridium functions as an immunomodulator. Its primary molecular target is the IgE-mediated allergic cascade. By introducing standardized amounts of specific allergens (proteins), Iridium forces the immune system to re-evaluate its 'threat assessment.'

1. 1Early Phase: Iridium binds to dendritic cells, which present the allergen to T-cells.
2. 2Shift in Cytokines: It triggers a switch from Th2 cytokines (IL-4, IL-5) to Th1 and Treg cytokines (IFN-gamma, IL-10).
3. 3B-Cell Modulation: This cytokine shift signals B-cells to stop producing IgE and start producing IgG4, which acts as a 'decoy' or 'blocking' antibody.

• Onset of Effect: Immunological changes begin within weeks, but clinical protection (reduction in symptoms) typically takes 3 to 6 months of consistent therapy.
• Duration: The protective effects of a full course of Iridium (3-5 years) can last for 5 to 10 years or longer after the treatment is stopped.
• Tolerance: Unlike many drugs, 'tolerance' to Iridium is the goal—the body becomes progressively less reactive to the allergen over time.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous/Local) |

| Protein Binding | N/A (Biological Extract) |

| Half-life (Proteins) | 2–8 hours (Systemic) |

| Tmax (Systemic) | 1–4 hours |

| Metabolism | Proteolysis (Tissue/Blood) |

| Excretion | Renal (Peptides/Amino acids) |

• Molecular Formula: Complex mixture of proteins (e.g., phospholipases, hyaluronidases).
• Solubility: Soluble in aqueous solutions (saline with 0.45% phenol).
• Structure: High-molecular-weight glycoproteins and polypeptides derived from standardized biological sources.

Iridium is categorized as a Standardized Insect Allergenic Extract [EPC]. It is related to other immunotherapy agents like Grass Pollen Extracts and Dust Mite Extracts, but it is uniquely standardized for venom potency (measured in micrograms of protein or Bioequivalent Allergy Units).